

# Jeffrey W Clark

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2166832/publications.pdf>

Version: 2024-02-01

131  
papers

5,286  
citations

136885

32  
h-index

91828

69  
g-index

135  
all docs

135  
docs citations

135  
times ranked

8109  
citing authors

#	ARTICLE	IF	CITATIONS
1	Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma. <i>JAMA Oncology</i> , 2018, 4, 963.	3.4	426
2	Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. <i>Journal of Clinical Oncology</i> , 2016, 34, 460-468.	0.8	363
3	Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers. <i>Nature Medicine</i> , 2019, 25, 1415-1421.	15.2	359
4	Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer. <i>JAMA Oncology</i> , 2019, 5, 1020.	3.4	353
5	Safety and Pharmacokinetics of the Dual Action Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor, BAY 43-9006, in Patients with Advanced, Refractory Solid Tumors. <i>Clinical Cancer Research</i> , 2005, 11, 5472-5480.	3.2	332
6	Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration. <i>Nature Medicine</i> , 2020, 26, 47-51.	15.2	255
7	Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX. <i>Annals of Surgery</i> , 2019, 269, 733-740.	2.1	235
8	Minimal Residual Disease Detection using a Plasma-only Circulating Tumor DNA Assay in Patients with Colorectal Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 5586-5594.	3.2	178
9	Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer. <i>Cancer Discovery</i> , 2015, 5, 1271-1281.	7.7	162
10	A protein and mRNA expression-based classification of gastric cancer. <i>Modern Pathology</i> , 2016, 29, 772-784.	2.9	142
11	Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 Skipping. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1242-1245.	0.5	140
12	Phase I Study of the Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (TAK-924/MLN4924) in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2016, 22, 847-857.	3.2	133
13	Prognosis and Clinicopathologic Features of Patients With Advanced Stage Isocitrate Dehydrogenase (IDH) Mutant and IDH Wild-Type Intrahepatic Cholangiocarcinoma. <i>Oncologist</i> , 2015, 20, 1019-1027.	1.9	112
14	Radiation therapy enhances immunotherapy response in microsatellite stable colorectal and pancreatic adenocarcinoma in a phase II trial. <i>Nature Cancer</i> , 2021, 2, 1124-1135.	5.7	112
15	A Phase 1/2 and Biomarker Study of Preoperative Short Course Chemoradiation With Proton Beam Therapy and Capecitabine Followed By Early Surgery for Resectable Pancreatic Ductal Adenocarcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 89, 830-838.	0.4	101
16	Protons versus Photons for Unresectable Hepatocellular Carcinoma: Liver Decompensation and Overall Survival. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 64-72.	0.4	99
17	Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis. <i>Lung Cancer</i> , 2019, 133, 96-102.	0.9	85
18	Crizotinib in Patients With MET-Amplified NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1017-1029.	0.5	84

#	ARTICLE	IF	CITATIONS
19	Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	82
20	Serial ctDNA Monitoring to Predict Response to Systemic Therapy in Metastatic Gastrointestinal Cancers. <i>Clinical Cancer Research</i> , 2020, 26, 1877-1885.	3.2	67
21	Clinical activity of crizotinib in advanced non-small cell lung cancer (NSCLC) harboring ROS1 gene rearrangement.. <i>Journal of Clinical Oncology</i> , 2012, 30, 7508-7508.	0.8	65
22	Crizotinib in patients (pts) with MET-amplified non-small cell lung cancer (NSCLC): Updated safety and efficacy findings from a phase 1 trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, 9062-9062.	0.8	65
23	A Phase II and Biomarker Study of Sorafenib Combined with Modified FOLFOX in Patients with Advanced Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2019, 25, 80-89.	3.2	62
24	Convergent Therapeutic Strategies to Overcome the Heterogeneity of Acquired Resistance in <i>BRAF</i> <sup>V600E</sup> Colorectal Cancer. <i>Cancer Discovery</i> , 2018, 8, 417-427.	7.7	61
25	Tumor Microenvironment Immune Response in Pancreatic Ductal Adenocarcinoma Patients Treated With Neoadjuvant Therapy. <i>Journal of the National Cancer Institute</i> , 2021, 113, 182-191.	3.0	49
26	Familial Gastric Cancers. <i>Oncologist</i> , 2015, 20, 1365-1377.	1.9	46
27	Evaluation of Statistical Designs in Phase I Expansion Cohorts: The Dana-Farber/Harvard Cancer Center Experience. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	3.0	45
28	Long-term outcomes and toxicities of a large cohort of anal cancer patients treated with dose-painted IMRT per RTOG 0529. <i>Advances in Radiation Oncology</i> , 2017, 2, 110-117.	0.6	45
29	Impact of Postoperative Complication and Completion of Multimodality Therapy on Survival in Patients Undergoing Gastrectomy for Advanced Gastric Cancer. <i>Journal of the American College of Surgeons</i> , 2020, 230, 912-924.	0.2	42
30	Efficacy and safety of crizotinib in patients with advanced ROS1-rearranged non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2013, 31, 8032-8032.	0.8	42
31	Improving staging of rectal cancer in the pelvis: the role of PET/MRI. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 1235-1245.	3.3	40
32	Rubitecan. <i>Expert Opinion on Investigational Drugs</i> , 2006, 15, 71-79.	1.9	35
33	A tunable delivery platform to provide local chemotherapy for pancreatic ductal adenocarcinoma. <i>Biomaterials</i> , 2016, 93, 71-82.	5.7	35
34	Intraoperative Radiotherapy in the Era of Intensive Neoadjuvant Chemotherapy and Chemoradiotherapy for Pancreatic Adenocarcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 607-612.	0.6	32
35	The Incidence, Risk Factors, and Outcomes With 5-Fluorouracil-Associated Coronary Vasospasm. <i>JACC: CardioOncology</i> , 2021, 3, 101-109.	1.7	31
36	Circulating Tumor DNA Predicts Pathologic and Clinical Outcomes Following Neoadjuvant Chemoradiation and Surgery for Patients With Locally Advanced Rectal Cancer. <i>JCO Precision Oncology</i> , 2021, 5, 123-132.	1.5	30

#	ARTICLE	IF	CITATIONS
37	Reverse Transcriptase Inhibition Disrupts Repeat Element Life Cycle in Colorectal Cancer. <i>Cancer Discovery</i> , 2022, 12, 1462-1481.	7.7	30
38	A phase I clinical and pharmacokinetic study of the dolastatin analogue cemadotin administered as a 5-day continuous intravenous infusion. <i>Cancer Chemotherapy and Pharmacology</i> , 2000, 46, 319-328.	1.1	28
39	Clinical impact of PET/MR in treated colorectal cancer patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 2260-2269.	3.3	28
40	Impact of MET inhibitors on survival among patients (pts) with <i>MET</i> exon 14 mutant ( <i>MET</i> <del>14</del> ) non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 8511-8511.	0.8	26
41	Cost-effectiveness of immune checkpoint inhibitors for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer. <i>Cancer</i> , 2019, 125, 278-289.	2.0	24
42	NCCN Oncology Research Program's Investigator Steering Committee and NCCN Best Practices Committee Molecular Profiling Surveys. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 1337-1346.	2.3	23
43	Intraoperative Radiation Therapy (IORT) for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (BR/LA PDAC) in the Era of Modern Neoadjuvant Treatment: Short-Term and Long-Term Outcomes. <i>Annals of Surgical Oncology</i> , 2020, 27, 1400-1406.	0.7	22
44	Impact of adjuvant therapy in patients with invasive intraductal papillary mucinous neoplasms of the pancreas. <i>Pancreatology</i> , 2020, 20, 722-728.	0.5	22
45	Impact of PET/MRI in the Treatment of Pancreatic Adenocarcinoma: a Retrospective Cohort Study. <i>Molecular Imaging and Biology</i> , 2021, 23, 456-466.	1.3	22
46	Primary tumor sidedness is an independent prognostic marker for survival in metastatic colorectal cancer: Results from a large retrospective cohort with mutational analysis. <i>Cancer Medicine</i> , 2018, 7, 2934-2942.	1.3	21
47	Pencil Beam Scanning Proton Beam Chemoradiation Therapy With 5-Fluorouracil and Mitomycin-C for Definitive Treatment of Carcinoma of the Anal Canal: A Multi-institutional Pilot Feasibility Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 90-95.	0.4	20
48	Molecular Characterization and Therapeutic Targeting of Colorectal Cancers Harboring Receptor Tyrosine Kinase Fusions. <i>Clinical Cancer Research</i> , 2021, 27, 1695-1705.	3.2	19
49	High IDO1 Expression Is Associated with Poor Outcome in Patients with Anal Cancer Treated with Definitive Chemoradiotherapy. <i>Oncologist</i> , 2019, 24, e275-e283.	1.9	18
50	Liver reirradiation for patients with hepatocellular carcinoma and liver metastasis. <i>Practical Radiation Oncology</i> , 2018, 8, 414-421.	1.1	17
51	Clinical impact of PET/MRI in oligometastatic colorectal cancer. <i>British Journal of Cancer</i> , 2021, 125, 975-982.	2.9	17
52	Adjuvant Therapy Completion Rates in Patients with Gastric Cancer Undergoing Perioperative Chemotherapy Versus a Surgery-First Approach. <i>Journal of Gastrointestinal Surgery</i> , 2016, 20, 172-179.	0.9	16
53	Enrichment of <i>HER2</i> Amplification in Brain Metastases from Primary Gastrointestinal Malignancies. <i>Oncologist</i> , 2019, 24, 193-201.	1.9	16
54	Impact of Single-organ Metastasis to the Liver or Lung and Genetic Mutation Status on Prognosis in Stage IV Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2020, 19, e8-e17.	1.0	15

#	ARTICLE	IF	CITATIONS
55	A Combination of Biochemical and Pathological Parameters Improves Prediction of Postresection Survival After Preoperative Chemotherapy in Pancreatic Cancer. <i>Annals of Surgery</i> , 2022, 275, 391-397.	2.1	15
56	Phase I clinical trial of 7-cyanoquinocarcinol (DX-52-1) in adult patients with refractory solid malignancies. <i>Cancer Chemotherapy and Pharmacology</i> , 2001, 48, 347-355.	1.1	14
57	Prognostic Significance of Surgical Margin Size After Neoadjuvant FOLFOX and/or FOLFIRI for Colorectal Liver Metastases. <i>Journal of Gastrointestinal Surgery</i> , 2017, 21, 1831-1840.	0.9	14
58	FOLFOX plus ziv-aflibercept or placebo in first-line metastatic esophagogastric adenocarcinoma: A double-blind, randomized, multicenter phase 2 trial. <i>Cancer</i> , 2019, 125, 2213-2221.	2.0	14
59	A phase 2 clinical trial of the heat shock protein 90 (HSP 90) inhibitor ganetespib in patients with refractory advanced esophagogastric cancer. <i>Investigational New Drugs</i> , 2020, 38, 1533-1539.	1.2	13
60	Pancreatic acinar cell carcinoma: A multi-center series on clinical characteristics and treatment outcomes. <i>Pancreatology</i> , 2021, 21, 1119-1126.	0.5	13
61	Phase II study of pembrolizumab in refractory esophageal cancer with correlates of response and survival. , 2021, 9, e002472.		13
62	TGF-B1 inhibition with losartan in combination with FOLFIRINOX (F-NOX) in locally advanced pancreatic cancer (LAPC): Preliminary feasibility and R0 resection rates from a prospective phase II study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 386-386.	0.8	13
63	Tivantinib for advanced hepatocellular carcinoma: is MET still a viable target?. <i>Lancet Oncology</i> , The, 2018, 19, 591-592.	5.1	12
64	Transcriptomic and Genomic Testing to Guide Individualized Treatment in Chemoresistant Gastric Cancer Case. <i>Biomedicines</i> , 2020, 8, 67.	1.4	12
65	Dose-escalation trial of the ALK, MET & ROS1 inhibitor, crizotinib, in patients with advanced cancer. <i>Future Oncology</i> , 2020, 16, 4289-4301.	1.1	12
66	Irradiation of anatomically defined pelvic subsites and acute hematologic toxicity in anal cancer patients undergoing chemoradiation. <i>Practical Radiation Oncology</i> , 2017, 7, e291-e297.	1.1	11
67	Chemoradiation-Related Lymphopenia and Its Association with Survival in Patients with Squamous Cell Carcinoma of the Anal Canal. <i>Oncologist</i> , 2020, 25, 1015-1022.	1.9	11
68	Standard fractionation external beam radiotherapy with and without intraoperative radiotherapy for locally recurrent rectal cancer: the role of local therapy in patients with a high competing risk of death from distant disease. <i>British Journal of Radiology</i> , 2017, 90, 20170134.	1.0	10
69	Recent progress in systemic treatment for lung cancer. <i>Current Opinion in Pulmonary Medicine</i> , 2018, 24, 355-366.	1.2	10
70	Are Staging Computed Tomography (CT) Scans of the Chest Necessary in Pancreatic Adenocarcinoma?. <i>Annals of Surgical Oncology</i> , 2018, 25, 3936-3942.	0.7	10
71	Care Patterns and Overall Survival in Patients With Early-Onset Metastatic Colorectal Cancer. <i>JCO Oncology Practice</i> , 2021, 17, e1846-e1855.	1.4	9
72	Potentially curative combination of TGF-b1 inhibitor losartan and FOLFIRINOX (FFX) for locally advanced pancreatic cancer (LAPC): R0 resection rates and preliminary survival data from a prospective phase II study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 4116-4116.	0.8	9

#	ARTICLE	IF	CITATIONS
73	Arterial involvement and resectability scoring system to predict R0 resection in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemoradiation therapy. <i>European Radiology</i> , 2022, 32, 2470-2480.	2.3	9
74	The efficacy and safety of cardio-protective therapy in patients with 5-FU (Fluorouracil)-associated coronary vasospasm. <i>PLoS ONE</i> , 2022, 17, e0265767.	1.1	9
75	The impact of neoadjuvant therapy for gastroesophageal adenocarcinoma on postoperative morbidity and mortality. <i>Journal of Surgical Oncology</i> , 2016, 113, 560-564.	0.8	8
76	Conditional Survival in Resected Pancreatic Ductal Adenocarcinoma Patients Treated with Total Neoadjuvant Therapy. <i>Journal of Gastrointestinal Surgery</i> , 2021, 25, 2859-2870.	0.9	8
77	Results and Molecular Correlates from a Pilot Study of Neoadjuvant Induction FOLFIRINOX Followed by Chemoradiation and Surgery for Gastroesophageal Adenocarcinomas. <i>Clinical Cancer Research</i> , 2021, 27, 6343-6353.	3.2	8
78	Phase I study of sapacitabine and seliciclib in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2016, 34, 2503-2503.	0.8	8
79	A phase II study of ipilimumab and nivolumab with radiation in metastatic pancreatic adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, 391-391.	0.8	8
80	Associations of baseline patient-reported outcomes with treatment outcomes in advanced gastrointestinal cancer. <i>Cancer</i> , 2021, 127, 619-627.	2.0	7
81	Phase Ib study of neoadjuvant chemoradiation (CRT) with midostaurin, 5-fluorouracil (5-FU) and radiation (XRT) for locally advanced rectal cancer: Sensitization of RAS mutant tumors.. <i>Journal of Clinical Oncology</i> , 2018, 36, e15674-e15674.	0.8	7
82	Using circulating tumor DNA (ctDNA) to predict surgical outcome after neoadjuvant chemoradiation for locally advanced pancreatic cancer (LAPC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 272-272.	0.8	7
83	Prospective Phase II Trials Validate the Effect of Neoadjuvant Chemotherapy on Pattern of Recurrence in Pancreatic Adenocarcinoma. <i>Annals of Surgery</i> , 2022, 276, e502-e509.	2.1	6
84	Phase II study of autophagy inhibition with hydroxychloroquine (HCQ) and preoperative (preop) short course chemoradiation (SCRT) followed by early surgery for resectable ductal adenocarcinoma of the head of pancreas (PDAC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 4118-4118.	0.8	5
85	Patterns of Failure and the Need for Biliary Intervention in Resected Biliary Tract Cancers After Chemoradiation. <i>Annals of Surgical Oncology</i> , 2020, 27, 5161-5172.	0.7	4
86	Neoadjuvant versus Postoperative Chemoradiotherapy is Associated with Improved Survival for Patients with Resectable Gastric and Gastroesophageal Cancer. <i>Annals of Surgical Oncology</i> , 2022, 29, 242-252.	0.7	4
87	FOLFIRINOX in locally advanced or metastatic pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, 313-313.	0.8	4
88	Impact of Treatment Sequencing on Survival for Patients with Locally Advanced Gastric Cancer. <i>Annals of Surgical Oncology</i> , 2021, 28, 2856-2865.	0.7	3
89	Effect of molecular genotyping to predict outcomes in patients with metastatic pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, 4128-4128.	0.8	3
90	Case 32-2018: A 36-Year-Old Pregnant Woman with Newly Diagnosed Adenocarcinoma. <i>New England Journal of Medicine</i> , 2018, 379, 1562-1570.	13.9	2

#	ARTICLE	IF	CITATIONS
91	Validation of the NSABP neoadjuvant rectal score (NAR) in a prospective phase II study evaluating an experimental regimen and a standard chemoradiation cohort with molecular genotyping.. Journal of Clinical Oncology, 2014, 32, 3599-3599.	0.8	2
92	Multi-institutional phase II study of high dose, hypofractionated proton beam therapy (HF-PBT) for unresectable primary liver cancers: Long term outcomes in patients (pts) with intrahepatic cholangiocarcinoma (ICC).. Journal of Clinical Oncology, 2015, 33, 4020-4020.	0.8	2
93	Outcomes following liver SBRT for metastatic pancreatic cancer.. Journal of Clinical Oncology, 2019, 37, 418-418.	0.8	2
94	Using circulating tumor DNA (ctDNA) to predict surgical outcome and postoperative recurrence following neoadjuvant chemoradiation (CRT) for borderline resectable/locally advanced rectal cancer (LARC).. Journal of Clinical Oncology, 2019, 37, 562-562.	0.8	2
95	FOLFIRINOX in locally advanced and metastatic pancreatic cancer.. Journal of Clinical Oncology, 2012, 30, e14615-e14615.	0.8	2
96	A multi-institutional phase II study of high-dose hypofractionated proton beam therapy (HF-PBT) for unresectable primary liver cancers: Long-term outcomes in patients (pts) with hepatocellular carcinoma (HCC).. Journal of Clinical Oncology, 2016, 34, 376-376.	0.8	2
97	Dose intensity of neoadjuvant FOLFIRINOX (FFX) in borderline and locally advanced pancreatic cancer (LAPC): A comparison to the adjuvant benchmark.. Journal of Clinical Oncology, 2019, 37, 392-392.	0.8	2
98	Targeted inhibition in tumors with ALK dependency. Lung Cancer: Targets and Therapy, 2013, 4, 1.	1.3	1
99	Clinical correlation with codon-specific mutations in metastatic colorectal cancer.. Journal of Clinical Oncology, 2016, 34, 3596-3596.	0.8	1
100	Circulating biomarkers in a phase II study of hypofractionated proton beam therapy (H-PBT) for hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC).. Journal of Clinical Oncology, 2016, 34, 4083-4083.	0.8	1
101	Intraoperative radiotherapy (IORT) in the era of intensive neoadjuvant chemotherapy and chemoradiotherapy for locally advanced and borderline resectable adenocarcinoma of the pancreas (PDAC).. Journal of Clinical Oncology, 2016, 34, 393-393.	0.8	1
102	FOLFIRINOX (F-NOX) followed by individualized radiation for borderline-resectable pancreatic cancer (BRPC): Toxicity, R0 resection, and interim survival data from a prospective phase II study.. Journal of Clinical Oncology, 2017, 35, 4113-4113.	0.8	1
103	Quantitative MR imaging biomarkers of tumor heterogeneity predict prognosis in metastatic colorectal lesions.. Journal of Clinical Oncology, 2017, 35, e15121-e15121.	0.8	1
104	Phase I study of onalespib, HSP90 inhibitor, and AT7519M, CDK9 inhibitor, in patients with advanced solid tumors.. Journal of Clinical Oncology, 2017, 35, TPS2617-TPS2617.	0.8	1
105	FOLFIRINOX (F-NOX) followed by individualized radiation for borderline-resectable pancreatic cancer: Preliminary toxicity and R0 resection rates from a prospective phase II study.. Journal of Clinical Oncology, 2017, 35, 368-368.	0.8	1
106	Multicenter phase II trial of pembrolizumab (pembro) in previously-treated metastatic esophageal cancer.. Journal of Clinical Oncology, 2018, 36, e16072-e16072.	0.8	1
107	Phase I/II study of preoperative (pre-op) short course chemoradiation (CRT) with proton beam therapy (PBT) and capecitabine (cape) followed by early surgery for resectable pancreatic ductal adenocarcinoma (PDAC) of the head.. Journal of Clinical Oncology, 2012, 30, 4021-4021.	0.8	1
108	Phase I study of sequential sapacitabine and seliciclib in patients with advanced solid tumors.. Journal of Clinical Oncology, 2012, 30, 3053-3053.	0.8	1



#	ARTICLE	IF	CITATIONS
109	HER2 positivity in brain metastases from gastrointestinal primary malignancies.. Journal of Clinical Oncology, 2018, 36, 61-61.	0.8	1
110	The immune milieu of anal squamous cell carcinoma and implications of IDO expression on outcome.. Journal of Clinical Oncology, 2018, 36, 659-659.	0.8	1
111	Drug Interactions: The Importance of Looking Inside Cancer Cells: Table 1.. Cancer Discovery, 2012, 2, 208-210.	7.7	0
112	ASO Visual Abstract: Neoadjuvant versus Postoperative Chemoradiotherapy Is Associated with Improved Survival in Patients with Resectable Gastric and Gastroesophageal Cancer. Annals of Surgical Oncology, 2021, 28, 690-691.	0.7	0
113	Immediate versus delayed adjuvant chemoradiation for resected pancreatic cancer: An analysis of local control and survival.. Journal of Clinical Oncology, 2012, 30, 301-301.	0.8	0
114	A phase I study of ADENSPM (N1, N11-diethylnorspermine) in patients with advanced hepatocellular carcinoma (HCC).. Journal of Clinical Oncology, 2013, 31, 260-260.	0.8	0
115	Mutational analysis of locally advanced rectal cancer and response to neoadjuvant chemoradiation.. Journal of Clinical Oncology, 2013, 31, 449-449.	0.8	0
116	Circulating oncometabolite 2-hydroxyglutarate (2HG) as a potential surrogate biomarker in patients with isocitrate dehydrogenase mutant (IDHm) intrahepatic cholangiocarcinoma (ICC).. Journal of Clinical Oncology, 2013, 31, 4125-4125.	0.8	0
117	Genetic, tissue, and plasma biomarkers of outcomes from a prospective study of neoadjuvant short course proton-based chemoradiation for resectable pancreatic ductal adenocarcinoma (PDAC).. Journal of Clinical Oncology, 2013, 31, 4047-4047.	0.8	0
118	DNA mutation frequencies in metastatic small bowel adenocarcinoma (mSBA) in comparison to gastric (mGC), colon (mCC), and rectal cancer (mRC): Continuum or cutpoint?. Journal of Clinical Oncology, 2013, 31, e14636-e14636.	0.8	0
119	A single-arm phase II trial of gemcitabine, oxaliplatin, and panitumumab in KRAS wild-type advanced biliary tract cancer.. Journal of Clinical Oncology, 2014, 32, 255-255.	0.8	0
120	A phase II trial of cabozantinib in patients with carcinoid and pancreatic neuroendocrine tumors.. Journal of Clinical Oncology, 2014, 32, TPS4157-TPS4157.	0.8	0
121	The impact of neoadjuvant therapy for gastroesophageal adenocarcinoma on postoperative morbidity and mortality.. Journal of Clinical Oncology, 2015, 33, 156-156.	0.8	0
122	Clinical characteristics and treatment outcomes of patients with metastatic, MET-amplified esophagogastric cancers.. Journal of Clinical Oncology, 2015, 33, 4043-4043.	0.8	0
123	MET-amplification (MET-amp) in relation to aggressive biology in esophagogastric cancer (EGC): An analysis of clinical outcomes of MET-amp vs non-MET-amp EGC.. Journal of Clinical Oncology, 2018, 36, 74-74.	0.8	0
124	A pilot feasibility study of definitive concurrent chemoradiation with pencil beam scanning proton beam in combination with 5-fluorouracil and mitomycin-c for carcinoma of the anal canal.. Journal of Clinical Oncology, 2018, 36, 733-733.	0.8	0
125	Nivolumab versus nivolumab with ipilimumab versus trifluridine/tipiracil for metastatic microsatellite instability-high colorectal cancer: A modeling decision analysis.. Journal of Clinical Oncology, 2018, 36, 829-829.	0.8	0
126	A phase 2 and biomarker study of sorafenib combined with FOLFOX in patients with advanced hepatocellular carcinoma (HCC).. Journal of Clinical Oncology, 2018, 36, 270-270.	0.8	0



#	ARTICLE	IF	CITATIONS
127	Analysis of DNA damage response (DDR) genes and tumor mutational burden (TMB) across 17,486 carcinomas of the tubular GI tract: Implications for therapy.. Journal of Clinical Oncology, 2018, 36, 43-43.	0.8	0
128	Preoperative chemoradiotherapy versus postoperative chemoradiotherapy for local advanced gastric or Siewert II/III GEJ cancer: A retrospective analysis.. Journal of Clinical Oncology, 2018, 36, 115-115.	0.8	0
129	Cost-effectiveness of nivolumab vs. ipilimumab/nivolumab vs. trifluridine/tipiracil or mFOLFOX6/cetuximab for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer.. Journal of Clinical Oncology, 2018, 36, e15134-e15134.	0.8	0
130	Abstract PO-097: Addition of losartan to FOLFIRINOX and chemoradiation reduces the expression of pro-invasive and immunosuppressive genes in locally-advanced pancreatic cancer. , 2021, , .		0
131	Abstract P061: Dendritic cell paucity in mismatch repair-proficient colorectal cancer liver metastases limits the efficacy of immune checkpoint blockade. , 2022, , .		0